FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
11.7.22
NovaQuest in the News
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest Capital Management to support continued development of the company’s antibody-cleaving enzyme technology platform across multiple therapeutic areas while extending the expected cash runway through 2024
7.18.22
TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry
5.25.22
